Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2024 Aug 13;17(9):sfae250.
doi: 10.1093/ckj/sfae250. eCollection 2024 Sep.

Semaglutide-associated kidney injury

Affiliations
Case Reports

Semaglutide-associated kidney injury

Farhana Begum et al. Clin Kidney J. .

Abstract

Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are multipurpose agents effective in improving glycemic control in patients with type 2 diabetes while also achieving weight loss and risk reduction of major cardiovascular (CV) events and chronic kidney disease progression. With their increased utility in diabetes, obesity, CV health and renal protection, the use of GLP-1RAs has increased. However, with this increased use, there have also been increased reports of associated kidney adverse events, including case reports of acute interstitial nephritis (AIN) associated with GLP-1RA use. We report the data from the Food and Drug Administration adverse event reporting system (FAERS) in relation to GLP-1RA use and adverse kidney events, with acute kidney injury being the most common. In addition, we report two cases of semaglutide-associated biopsy-proven AIN and one with associated podocytopathy. To our knowledge, this is the first case of biopsy-proven AIN with podocytopathy associated with semaglutide use. Both patients experienced complete remission shortly after discontinuing semaglutide and undergoing immunosuppressive therapy. Further analysis of the FAERS database revealed 17 cases of proteinuria and 1 case of glomerulonephritis associated with semaglutide in the FAERS database, however no further information was available. While further research is needed to establish causality, this case series adds to the growing body of literature that semaglutide is associated with AIN and adds a new association, semaglutide with AIN and podocytopathies. While the overall clinical and mortality benefits of GLP-1RAs may outweigh the rarer risks, prescribers need to be aware of these associations, particularly as the use of GLP-1RAs continues to expand.

Keywords: AIN; AKI; GLP1 agonist; acute interstitial nephritis; diffuse podocytopathy; minimal change disease; podocytopathy; semaglutide.

PubMed Disclaimer

Conflict of interest statement

K.D.J. reports consultancy agreements with PMV pharmaceuticals, Decipher, Otsuka, George Clinicals, Calliditas, Novartis and Citrus Oncology; reports honoraria from the American Society of Nephrology and Lexicomp; is a paid contributor to UpToDate.com and is section editor for Onconephrology for Nephrology Dialysis Transplantation; serves on the editorial boards of American Journal of Kidney Diseases, CJASN, Clinical Kidney Journal, Frontiers in Nephrology, Journal of Onco-Nephrology and Kidney International; and serves as the Editor-in-Chief of ASN Kidney News. R.W. is member of the editorial board of Clinical Kidney Journal. All other authors have nothing to disclose.

Figures

Figure 1:
Figure 1:
From Case 1. Image (A) periodic acid–Schiff (PAS) Patchy infiltrates with associated tubulitis and tubular injury characterized by epithelial flattening and attenuated brush borders (PAS ×200). Image (B) hematoxylin and eosin (H&E) 20, H&E 40: infiltrates comprising of mononuclear inflammatory cells with scattered eosinophils. There is evidence of acute tubular injury with flattening of epithelial cells and focal mild tubulitis (H&E ×200; H&E ×400).

References

    1. Hinnen D. Glucagon-like peptide 1 receptor agonists for type 2 diabetes. Diabetes Spectr 2017;30:202–10. 10.2337/ds16-0026 - DOI - PMC - PubMed
    1. Marso SP, Bain SC, Consoli A et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834–44. 10.1056/NEJMoa1607141 - DOI - PubMed
    1. Wilding JPH, Batterham RL, Calanna S et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989–1002. 10.1056/NEJMoa2032183 - DOI - PubMed
    1. Lincoff AM, Brown-Frandsen K, Colhoun HM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221–32. 10.1056/NEJMoa2307563 - DOI - PubMed
    1. Perkovic V, Tuttle KR, Rossing P et al. FLOW Trial Committees and Investigators . Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes. N Engl J Med 2024;391:109–21. 10.1056/NEJMoa2403347 - DOI - PubMed

Publication types

LinkOut - more resources